Skip to main content

Michael Anthony Moody

J. Buren Sidbury Distinguished Professor of Pediatrics
Pediatrics, Infectious Diseases
Box 106016 DUMC, Durham, NC 27710
Rm 2139, 27 Alexandria Way, Room 2135 / DUMC Box 106016, Durham, NC 27703

Research Interests


I am currently funded to study the immune response to influenza, HIV-1, and syphilis.  As part of this, my laboratory is investigating the antibody response to these pathogens and quantifying the diversity of Fc-receptors that interact with these antibodies to mediate immune activity.

Selected Grants


Stimulating Access to Research in Residency (StARR) - NIAID

Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 2018 - 2029

A Global Syphilis Vaccine Targeting Outer Membrane Proteins of Treponema pallidum

ResearchPrincipal Investigator · Awarded by National Institute of Allergy and Infectious Diseases · 2024 - 2029

Structure-function analysis of infection- and vaccine-induced B-cell repertoires

ResearchPrincipal Investigator · Awarded by Boston Children's Hospital · 2023 - 2028

CIVICs C (75N93019C00054) Option 14

ResearchInvestigator · Awarded by National Institutes of Health · 2022 - 2026

CIVICs A - Option 23K

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2024 - 2026

CIVICs A - Option 22C

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2024 - 2026

Heterosubtypic immunity to influenza virus mediated by MHC-E-restricted memory NK cells

ResearchCollaborator · Awarded by National Institute of Allergy and Infectious Diseases · 2021 - 2026

Research Training in Allergy and Clinical Immunology

Inst. Training Prgm or CMEMentor · Awarded by University of North Carolina - Chapel Hill · 2000 - 2026

CIVICs A - Option 23H

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2022 - 2026

A biorepository of specimens for syphilis diagnostics (Bio4S) collected from well-characterized syphilis patients

ResearchPrincipal Investigator · Awarded by University of North Carolina - Chapel Hill · 2022 - 2026

Duke Center for Advancement of Child Health (CAtCH).

Inst. Training Prgm or CMEMentor · Awarded by Eunice Kennedy Shriver National Institute of Child Health and Human Development · 2021 - 2026

Infectious Diseases in Africa (IDA) Training Symposium for Next Gen Scientists

ConferenceCollaborator · Awarded by National Institutes of Health · 2024 - 2026

CIVICS A Opt 7

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2025 - 2026

CIVICS Component C - Option 5

ResearchInvestigator · Awarded by National Institutes of Health · 2019 - 2025

CIVICS A Opt 23I Soluble multivalent hemagglutinin immunogens to improve seasonal vaccines

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2023 - 2025

CIVICs A Opt 22B Development of a model to assess maternal antibody interference in NHPs

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2023 - 2025

CIVICs A Option 22A Preclinical testing of 20 HA mRNA-LNP vaccine

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2023 - 2025

CIVICs A Opt 23J - Modality testing for InvVax invariant influenza vaccine and possible synergy between T cell and antibody vaccines

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2023 - 2025

CIVICS Component A - Option 5

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2019 - 2025

CIVICS A Opt 28A

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2024 - 2025

CIVICS A Opt 12E

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2024 - 2025

CIVICs A Option 12C Viral Stock and Critical Reagent Propagation for CIVICs Program Use

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2023 - 2025

Interdisciplinary Research Training Program in AIDS

Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2010 - 2025

CIVICs A - DCVC Proposed Option 10C

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2024 - 2025

CIVICs A - DCVC Proposed Option 9D

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2024 - 2025

Immunogenicity and risk of autoimmune cross-reactivity of COVID-19 mRNA vaccines in SLE - RRF Investigator Award

ResearchMentor · Awarded by Rheumatology Research Foundation · 2022 - 2025

Emerging Infectious Diseases - Coordination Center

ResearchPrincipal Investigator · Awarded by Research Triangle Institute International · 2020 - 2025

Immunological Correlates of Syphilis Protection

ResearchPrincipal Investigator · Awarded by University of Connecticut · 2019 - 2025

CIVICs A - Option 23G

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2022 - 2024

EQAPOL - Years 2017 to 2024 - BASE

ResearchDirector · Awarded by National Institutes of Health · 2017 - 2024

COVID-19 Adaptive VAriant Immunologic Landscape Trial or COVAIL Trial

Clinical TrialInvestigator · Awarded by Leidos Biomedical Research, Inc. · 2022 - 2024

Transplant Infectious Diseases Interdisciplinary Research Training Grant (TIDIRTG)

Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2018 - 2024

CIVICs A - DCVC Proposed Option 9C

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2023 - 2024

CIVICs A - DCVC Proposed Option 10B

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2023 - 2024

CIVICs A - Option 18D

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2022 - 2024

CIVICs A - Option 23E

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2021 - 2024

CIVICs A - Option 23D

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2021 - 2024

Genomic epidemiology of Treponema pallidum strains infecting women and men in low-income countries to inform syphilis vaccine development (INV-036560)

ResearchPrincipal Investigator · Awarded by University of North Carolina - Chapel Hill · 2021 - 2024

CIVICs A - Option 23F

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2021 - 2024

CIVICs A - Option 12B

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2022 - 2024

Vaccine and Treatment Evaluation Units (VTEU)

ResearchInvestigator · Awarded by National Institutes of Health · 2013 - 2023

CIVICs A - Option 9B

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2022 - 2023

CIVICs A - Option 10A

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2022 - 2023

CORonavirus VAriant Sequencing (CORVASEQ) Surveillance Network

ResearchInvestigator · Awarded by University of North Carolina - Chapel Hill · 2021 - 2023

Immunomodulatory Biomaterials via Peptide and Protein Self-Assembly

ResearchCollaborator · Awarded by National Institutes of Health · 2009 - 2023

CIVICs A - Option 12A

ResearchPrincipal Investigator · Awarded by National Institute of Allergy and Infectious Diseases · 2021 - 2023

CIVICs A - Option 23A

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2020 - 2022

CIVICs A - Option 9A

ResearchPrincipal Investigator · Awarded by National Institute of Allergy and Infectious Diseases · 2021 - 2022

Early life B cell responses and inflammation following SARS-CoV-2 infection

ResearchCollaborator · Awarded by National Institutes of Health · 2021 - 2022

VTEU Task Area A - FY.2020.A1B1C1D1.0123 - Option 1

ResearchSenior Investigator · Awarded by National Institutes of Health · 2020 - 2021

Role of neutralizing antibodies in HIV-1-infected and vaccinated mothers in MTCT

ResearchCollaborator · Awarded by National Institutes of Health · 2016 - 2021

HVTN Phase 1 Protocol Funding

Clinical TrialPrincipal Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2018 - 2020

International Maternal Pediatric Adolescent AIDS Clinical Trial (IMPAACT) Group

ResearchCo-Principal Investigator · Awarded by University of California - Los Angeles · 2016 - 2020

VTEU Task Area A - FY.2020.A1B1C1D1.0123 - Base

ResearchSenior Investigator · Awarded by National Institutes of Health · 2019 - 2020

VTEU RTOP FY.2019.A1B1C1D1.0103 - Task A - Base

ResearchSenior Investigator · Awarded by National Institutes of Health · 2018 - 2019

CISA - 2017 TO# 07 - TDAP IIV in Pregnant Women (LEAD) Logical Follow-On - Option 3

ResearchInvestigator · Awarded by Centers for Disease Control and Prevention · 2017 - 2018

CISA - 2017 TO# 07 - TDAP IIV in Pregnant Women (LEAD) Logical Follow-On - Option 1

ResearchInvestigator · Awarded by Centers for Disease Control and Prevention · 2017 - 2018

CISA - 2017 TO# 07 - TDAP IIV in Pregnant Women (LEAD) Logical Follow-On - Option 2

ResearchInvestigator · Awarded by Centers for Disease Control and Prevention · 2017 - 2018

CISA: 2015 CISA 03 - Lead Site Optional Task 1 (Combined Options 1-11): Additional Subjects for Maternal Tdap and IIV Study (Lead)

Clinical TrialCo Investigator · Awarded by Centers for Disease Control and Prevention · 2016 - 2018

VTEU FY.2018.A1B1C1D1.0077 Task Area A - Base

ResearchSenior Investigator · Awarded by National Institutes of Health · 2017 - 2018

VTEU Task B Option 2 - FY.2017.A1B1C1D1.0048

ResearchSenior Investigator · Awarded by National Institutes of Health · 2017 - 2018

CARE Duke-UNC Latency Biomarker Supplement Year 2

ResearchCo Investigator · Awarded by University of North Carolina - Chapel Hill · 2016 - 2018

Broad neutralizing antibodies against HIV-1 from RV217 participants

ResearchPrincipal Investigator · Awarded by Henry M. Jackson Foundation · 2014 - 2018

VTEU Task Area B Option 2 Protocol FY.2016.B1.0026

ResearchSenior Investigator · Awarded by National Institutes of Health · 2016 - 2017

EQAPOL Option 47

ResearchMedical Director · Awarded by National Institutes of Health · 2011 - 2017

EQAPOL - Option 48 - 2016 to 2017 - LUMINEX

ResearchMedical Director · Awarded by National Institutes of Health · 2010 - 2017

EQAPOL - 2016 to 2017 - Option 6 - BASE

ResearchMedical Director · Awarded by National Institutes of Health · 2010 - 2017

EQAPOL Option 5

ResearchMedical Director · Awarded by National Institutes of Health · 2010 - 2017

B-cell repertoire analysis in influenza vaccination and infection

ResearchCo Investigator · Awarded by Boston Children's Hospital · 2015 - 2017

VTEU Task A Option 1 - FY.2017.A1B1C1D1.0048

ResearchSenior Investigator · Awarded by National Institutes of Health · 2017 - 2017

VTEU Task A Base - FY.2017.A1B1C1D1.0048

ResearchSenior Investigator · Awarded by National Institutes of Health · 2016 - 2017

Focus 1: Detection of HIV Antigen-Positive Cells

ResearchCo Investigator · Awarded by University of North Carolina - Chapel Hill · 2016 - 2017

VTEU Task Area B Option 2 Protocol FY.2016.B1.0026

ResearchSenior Investigator · Awarded by National Institutes of Health · 2016 - 2017

Structure-function Analysis of Infection and Vaccine Induced B-Cell Reoertiures-Supplement

ResearchPrincipal Investigator · Awarded by Boston Children's Hospital · 2015 - 2016

VTEU Task Area A, Base Protocol FY.2016.A1.0026

ResearchSenior Investigator · Awarded by National Institutes of Health · 2015 - 2016

VTEU Task Area A - FY.2015.A1.0016 Base

ResearchSenior Investigator · Awarded by National Institutes of Health · 2014 - 2015

VTEU 12-0016: Task Area C: Protocol implementation

Clinical TrialInvestigator · Awarded by National Institutes of Health · 2014 - 2015

Subcontract from UAB for Tetramer Production

ResearchPrincipal Investigator · Awarded by University of Alabama at Birmingham · 2014 - 2014

Mucosal antibody protection against postnatal SIV transmission in natural hosts of SIV

ResearchCo Investigator · Awarded by National Institutes of Health · 2012 - 2014

External Relationships


  • Grid Therapeutics, LLC

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.